SCHEMBL25341920

SCHEMBL25341920

Clc1cc(N2CCOCC2)c2nn(C3CC3)cc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 2/20 0.39
MAPK1 P28482 1/20 0.37
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36
SOS1 Q07889 1/20 0.36
KMT2A Q03164 3/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
NCF1 P14598 1/20 0.34
ALDH3A1 P30838 1/20 0.33
ALDH1A3 P47895 1/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
DYRK1A Q13627 1/20 0.33
PDE10A Q9Y233 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31356908 0.82 RECQL (0.43) MAPTSMN1; SMN2PIK3CD
SCHEMBL31356922 0.82 KMT2A (0.37) MAPTKMT2APIK3CDHPGDTSHR
SCHEMBL25341884 0.80 MAPT (0.41) MAPTSMN1; SMN2RAB9AMAPK1GAA
SCHEMBL31356912 0.79 USP30 (0.48) SMN1; SMN2PIK3CD
SCHEMBL25974053 0.79 MAPT (0.36) MAPTSMN1; SMN2RAB9AMAPK1GAA
SCHEMBL25974051 0.76 SOS1 (0.40) MAPTSMN1; SMN2RAB9AMAPK1GAA
SCHEMBL25342026 0.76 MAPT (0.39) MAPTSMN1; SMN2RAB9AMAPK1GAA
SCHEMBL13961185 0.73 TLR8 (0.36)
SCHEMBL2428960 0.73 GRM2 (0.38)
SCHEMBL25341630 0.72 GRIA1 (0.39) MAPTSMN1; SMN2RAB9ASOS1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4472968-A1 INHIBITORS OF RAF KINASES PIERRE FABRE MEDICAMENT (FR) 2024-12-11 EP disclosed
CN-118974036-A Inhibitors of RAF kinase 皮埃尔法布雷医药公司 2024-11-15 CN disclosed
US-20240182467-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2024-06-06 US disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 US disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 US disclosed
US-11814384-B2 Inhibtors of Raf kinases KINNATE BIOPHARMA INC. (US) 2023-11-14 US disclosed
US-20230303566-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-09-28 US disclosed
US-20230303566-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-09-28 US disclosed
WO-2023150681-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2023-08-10 WO disclosed
WO-2023150681-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182467-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF MAPT 2859/4885SMN1; SMN2 3700/4885RAB9A 1050/4885
US-20230303566-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF MAPT 2859/4885SMN1; SMN2 3700/4885RAB9A 1050/4885
US-11814384-B2 Inhibtors of Raf kinases RAF1, BRAF, ARAF MAPT 3440/4885SMN1; SMN2 4332/4885RAB9A 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.